Shang Hai Zheng Quan Bao·2025-12-30 19:51Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the initiation of Phase I clinical trials for its integrated diagnostic and therapeutic nuclear medicine project SRT-007, targeting PSMA-positive metastatic castration-resistant prostate cancer in mainland China [2]. Drug Information and Research Status - The SRT-007 project includes two injectable radioactive drugs: Gallium [68Ga] PSMA-0057 for diagnosis and Lutetium [177Lu] PSMA-0057 for treatment [3]. - As of November 2025, the cumulative R&D investment for SRT-007 is approximately RMB 32.19 million (unaudited), which includes licensing fees [3]. - The only approved drug targeting the same receptor globally is NOVARTIS AG's Pluvicto, which reported global sales of USD 1.392 billion in 2024 [3].